Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Research on Effective Strategies After Immunotherapy for Mismatch Repair-deficient Early-stage GI Tumors (RESIST)

14 de setembro de 2026 atualizado por: University Hospital, Basel, Switzerland

This cohort study is divided into two parts:

Part A: Registry Cohort All patients with non-metastatic, MMRd/MSI-H colorectal cancers (and other gastrointestinal cancers for exploratory analysis) who have signed the general research consent will be included in a prospective registry. This includes patients who undergo primary surgical resection (+/- neoadjuvant/adjuvant therapy) or following immunotherapy, regardless of response.

Part A is a multicenter observational registry with both prospective and retrospective enrolment. Prospective enrolment includes eligible patients entered into the registry after activation of the study at the respective participating site. Retrospective enrolment includes eligible patients diagnosed on or after 1 January 2024 whose clinical data were generated prior to registry activation. Both prospectively and retrospectively enrolled patients contribute to the registry analyses.

Part B: Active Surveillance Cohort (Surveillance Study) A subset of patients from Part A who achieve a complete or near-complete response to ICI therapy, wish to avoid surgery, and are deemed appropriate for non-operative management by a multidisciplinary tumor board are offered inclusion in a phase II surveillance study (Part B). Patients enrolled in Part B will be analysed for the primary endpoint.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

Background and Rationale: Mismatch repair-deficient (MMRd) or microsatellite instability-high (MSI-H) gastrointestinal (GI) cancers represent a distinct molecular subtype characterized by high tumor mutational burden and increased immunogenicity. Immune checkpoint inhibitors (ICIs) have demonstrated remarkable efficacy in this population, with recent studies showing high rates of pathological complete response (pCR) when used in the neoadjuvant setting for non-metastatic GI cancers and colorectal cancers in particular. These results raise important questions about the necessity of surgical resection in patients who achieve complete clinical response (cCR) after ICI therapy.

Avoiding surgery in patients with complete response through an active surveillance approach could significantly reduce treatment-related morbidity and improve quality of life for selected patients. However, this strategy remains investigational and robust clinical evidence is lacking regarding its safety, long-term oncologic outcomes and appropriate selection criteria. Our study seeks to address this gap by evaluating response-guided, non-operative management in patients with non-metastatic MMRd/ MSI-H GI tumors treated primarily with immunotherapy.

Objectives: The primary objective of this study is to evaluate 2-year relapse-free survival (RFS) in patients with non-metastatic, mismatch repair-deficient (MMRd) or microsatellite instability-high (MSI-H) in patients with stage II/III colorectal cancer who achieve a complete or near-complete response following primary treatment with immune checkpoint inhibitors (ICIs) who enter Part B of the study (surveillance study).

Method: Eligible patients may receive immune checkpoint inhibitor (ICI) therapy as the primary treatment for mismatch repair-deficient (MMRd) or microsatellite instability-high (MSI-H), locally advanced, non-metastatic gastrointestinal cancer according to local practice. Treatment regimens include PD-(L)1 monotherapy (e.g., pembrolizumab, atezolizumab) or combination ICI therapy (e.g., nivolumab plus ipilimumab), administered at the discretion of the treating oncologist for up to 6 months (in case of near complete response ICI may be continued up to a total of 12 months following multidisciplinary evaluation).

Patients who do not achieve a complete or near-complete clinical response-or who are not eligible or not willing to undergo non-operative management-proceed to standard oncological surgery (with or without neo-/adjuvant systemic therapy), in accordance with clinical guidelines. Postoperatively, they receive routine oncological follow-up per institutional standards and remain in registry cohort (Part A).

Patients who demonstrate a complete or near-complete clinical response to ICI and are considered eligible for non-surgical management (based on multidisciplinary evaluation), enter an intensified surveillance program in lieu of immediate surgery (Part B).

The active surveillance includes Clinical assessments, Cross-sectional imaging (e.g., CT or MRI) , Endoscopic evaluations at defined intervals and Facultative ctDNA testing 6 months after completion of immunotherapy (Part B)

Tipo de estudo

Observacional

Inscrição (Estimado)

234

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

  • Suíça
      • Basel, Suíça, 4031
        • Recrutamento
        • Universitätsspital Basel
        • Contato:
          • Viviane Hess, Prof. Dr. med.
          • Número de telefone: +41 61 265 50 59
          • E-mail: viviane.hess@usb.ch
      • Biel, Suíça, 2501
        • Recrutamento
        • Spitalzentrum Biel
        • Contato:
      • Lucerne, Suíça, 6000
        • Recrutamento
        • Luzerner Kantonsspital
        • Contato:
          • Jörn Markus Gass, PD Dr. med.
          • Número de telefone: +41 41 205 45 39
          • E-mail: markus.gass@luks.ch

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Método de amostragem

Amostra Não Probabilística

População do estudo

The study population includes adult patients with non-metastatic MSI-H/MMRd gastrointestinal cancers, specifically colorectal (colon and rectal) cancer as well as gastro-oesophageal and gastric adenocarcinoma. Eligible participants must have achieved a complete or near-complete clinical response following immune checkpoint inhibitor therapy, with no radiologic, endoscopic, or histologic evidence of residual disease at the time of response assessment. Patients are enrolled into a structured active surveillance program instead of undergoing immediate surgical resection. Individuals with metastatic disease, insufficient response to immunotherapy or contraindications to surveillance procedures are excluded.

Descrição

Inclusion Criteria:

Part A and Part B:

  • Consent and Capacity:
  • Participant is 18 years of age or older.
  • Participant is legally competent and able to provide informed consent.
  • Participant has provided the appropriate written consent
  • Diagnosis: Histologically confirmed gastro-oesophageal, colon or rectum cancer, showing mismatch repair-deficiency (MMRd) by immunohistochemistry (loss of immunoreactivity for at least one of the following proteins: MLH1, PMS2, MSH2 and/or MSH6).
  • Clinical Stage: Non-metastatic, locally advanced disease, defined as:
  • cT2-T4, cN0-2, cM0 for gastro-oesophageal or rectum cancer
  • cT4 and/or cN+, cM0 for colon cancer
  • Therapy with immune checkpoint inhibitor (ICI) as primary treatment, either:
  • Combination ICI therapy (e.g., anti-PD-1 plus anti-CTLA-4 such as nivolumab + ipilimumab) or
  • Single-agent ICI therapy (e.g., pembrolizumab, atezolizumab, or other anti- PD(L)1 agents)

Part B only:

  • Patient consents to participate in surveillance study
  • Complete or near complete response (*) to primary ICI treatment, as determined by local multidisciplinary team (MDT) assessment, based on restaging 8 weeks after termination of the ICI treatment:
  • Radiological imaging (CT/MRI/PET-CT),
  • Endoscopic findings, and

  • Clinical parameters (e.g., normalization of tumor markers, absence of symptoms **)

    • Note: in case of near complete response up to a total of 12 months of ICI is allowed following multidisciplinary team (MDT) discussion. After diagnosis of a near-complete response, tumor reassessments should be performed every 3 months up to a total treatment period of 12 months. If a complete tumor response is observed within the 12-month period, it should be recorded as the best overall response.

      • Note: Assessment of complete or near complete response does not incorporate ctDNA test results

Exclusion Criteria:

  • Recurrent Disease: Known history of previously treated gastrointestinal cancer with recurrence at time of inclusion.
  • Metastatic Disease: Evidence of distant metastases (M1) at any point prior to or during ICI therapy.
  • Other Malignancies: Active second malignancy (excluding non-melanoma skiN cancer or in-situ cervical carcinoma) that may interfere with study outcomes or surveillance.

Part B only:

  • Inadequate response to ICI: Patients with progressive disease, stable disease, or partial response deemed unsuitable for non-operative management.
  • Prior Treatment: Any prior systemic therapy, radiotherapy or surgery for the current colon cancer diagnosis before ICI treatment (except biopsy)
  • Medical or Psychiatric Conditions: Significant comorbid conditions or psychiatric illness that, in the opinion of the investigator, would impair the patient's ability to comply with protocol requirements, including surveillance.
  • Logistical Barriers: Social, geographic, or organizational factors (e.g., lack of access to regular follow-up care, inability to attend surveillance visits) that would prevent adherence to the active surveillance protocol.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
Active Surveillance after ICI response instead of surgery
Participants with mismatch repair-deficient (MMRd) or microsatellite instability-high (MSI-H) stage II/III gastrointestinal cancer who achieve a complete or near-complete response after immune checkpoint inhibitor (ICI) therapy enter a structured active surveillance program instead of undergoing immediate surgery. Surveillance includes scheduled radiologic imaging, endoscopic evaluation, clinical assessment, and biomarker monitoring to detect relapse early and allow timely salvage treatment.
Outro: Active surveillance after complete response to immunotherapy in MMRd GI cancers

Eligible patients may receive immune checkpoint inhibitor (ICI) therapy as the primary treatment for mismatch repair-deficient (MMRd) or microsatellite instability-high (MSI-H), locally advanced, non-metastatic gastrointestinal cancer according to local practice. In case of near complete response ICI may be continued up to a total of 12 months following multidisciplinary evaluation.

Part A includes all patients with stage II or III colorectal cancer (esophageal adenocarcinoma, gastric cancer will be allowed as well) confirmed as MMRd/MSI-H. Patients are enrolled regardless of treatment strategy, including those receiving immune checkpoint inhibitor (ICI) therapy or primary surgery.

A subset of patients from Part A who achieve a complete or near-complete response to ICI therapy, wish to avoid surgery, and are deemed appropriate for non-operative management by a multidisciplinary tumor board are offered inclusion in a phase II active surveillance protocol (Part B).

Outros nomes:
  • watch and wait
Standard of Care Cohort
Patients that receive an operation to remove the primary tumour after completion of immunecheckpoint therapy for MSI high colorectal cancer (resp. other MSI high GI cancer).
Outro: Stand of Care
Patients in the Standard of care Arm (Arm A) will receive a resection of the primary tumour after completion of the immunecheckpoint inhibition therapy.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Relapse-Free Survival (RFS)
Prazo: 24 months
The proportion of patients with colorectal cancers who remain free from local, regional, or distant recurrence at 24 months after achieving a complete or near-complete clinical response to immune checkpoint inhibitor therapy and undergoing active surveillance. Recurrence is defined as radiologic, endoscopic, or histologic evidence of tumor regrowth requiring salvage surgery or systemic treatment.
24 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Relapse-Free Survival - other GI Cancers
Prazo: 24 months
applied to patients with non-metastatic MMRd/MSI-H gastroesophageal or other GI cancers entering active surveillance.
24 months
Clinical Complete Response (cCR) Rate
Prazo: 12 months
Proportion of patients achieving clinical complete response, near-complete response, partial response, stable disease, or progressive disease following ICI therapy, assessed by radiologic, endoscopic, clinical criteria, and biopsy results.
12 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

University Hospital, Basel, Switzerland

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de setembro de 2026

Conclusão Primária (Estimado)

31 de agosto de 2033

Conclusão do estudo (Estimado)

31 de agosto de 2033

Datas de inscrição no estudo

Enviado pela primeira vez

14 de setembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

14 de setembro de 2026

Primeira postagem (Real)

18 de setembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

14 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • RESIST

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever